Skip to content

Perrigo downgraded to sell by RBC

June 5, 2017

** Perrigo falling 3.5 pct in light volume premarket as RBC drops its rating on stock to underperform, saying drugmaker’s core consumer business erosion is a ‘new normal’ as pressure on Rx pricing and market share continues

** RBC, which had rated PRGO sector perform, cuts its PT from $66 to $60, lowest on the Street

** Pressure seen in co’s generic business well understood, “but this segment is set to provide a multiyear EPS drag on the consolidated business without the pipeline to offset that headwind,” analyst Randall Stanicky writes in note

** Downplays bullish view that PRGO selling its generics business could unlock stock’s value, saying standalone consumer EPS base likely overestimated as is valuation of slower-growing consumer outlook

** Stanicky rated 2 out of 5 stars by TR StarMine for his recommendation performance on PRGO

** Now, of 16 covering analysts, 3 rate PRGO “sell” or equivalent, 4 recommend buying, 9 “hold”; median PT $79.50

http://bit.ly/2sxzSQB

Advertisements

From → Uncategorized

Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: